IRIS
BOCCHIA, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.942
EU - Europa 19.170
AS - Asia 9.844
SA - Sud America 2.186
AF - Africa 217
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 14
Totale 54.404
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.657
GB - Regno Unito 4.265
RU - Federazione Russa 4.184
CN - Cina 3.652
SG - Singapore 3.126
IT - Italia 2.604
IE - Irlanda 2.598
BR - Brasile 1.854
UA - Ucraina 1.375
SE - Svezia 1.194
DE - Germania 934
HK - Hong Kong 838
FR - Francia 825
KR - Corea 622
VN - Vietnam 596
FI - Finlandia 570
IN - India 267
CA - Canada 142
AR - Argentina 130
NL - Olanda 128
BD - Bangladesh 116
TR - Turchia 99
JP - Giappone 90
PL - Polonia 90
MX - Messico 88
IQ - Iraq 71
BE - Belgio 67
ZA - Sudafrica 62
ES - Italia 57
EC - Ecuador 54
AT - Austria 49
CZ - Repubblica Ceca 48
UZ - Uzbekistan 39
MA - Marocco 38
ID - Indonesia 37
IR - Iran 35
VE - Venezuela 35
SA - Arabia Saudita 33
PK - Pakistan 31
CI - Costa d'Avorio 29
CO - Colombia 27
LT - Lituania 27
PY - Paraguay 25
AU - Australia 24
CL - Cile 23
EE - Estonia 20
AZ - Azerbaigian 18
EG - Egitto 18
TN - Tunisia 18
AE - Emirati Arabi Uniti 17
DO - Repubblica Dominicana 17
JO - Giordania 16
KE - Kenya 16
KZ - Kazakistan 16
PE - Perù 16
CH - Svizzera 15
IL - Israele 15
PH - Filippine 15
DZ - Algeria 14
GR - Grecia 13
MY - Malesia 13
BO - Bolivia 12
PT - Portogallo 11
SK - Slovacchia (Repubblica Slovacca) 11
NP - Nepal 10
RO - Romania 10
BG - Bulgaria 9
LB - Libano 9
RS - Serbia 9
UY - Uruguay 9
DK - Danimarca 8
EU - Europa 8
JM - Giamaica 8
HN - Honduras 7
HR - Croazia 7
LV - Lettonia 7
PS - Palestinian Territory 7
TT - Trinidad e Tobago 7
HU - Ungheria 6
NZ - Nuova Zelanda 6
OM - Oman 6
PA - Panama 6
BH - Bahrain 5
KG - Kirghizistan 5
LA - Repubblica Popolare Democratica del Laos 5
LK - Sri Lanka 5
LU - Lussemburgo 5
NG - Nigeria 5
TH - Thailandia 5
AL - Albania 4
AO - Angola 4
ET - Etiopia 4
MD - Moldavia 4
QA - Qatar 4
AM - Armenia 3
BY - Bielorussia 3
GA - Gabon 3
GE - Georgia 3
IM - Isola di Man 3
MN - Mongolia 3
Totale 54.358
Salva come PNG Salva come JPEG
Città #
Southend 3.769
Dallas 3.045
Dublin 2.583
Fairfield 2.448
Singapore 1.844
Ashburn 1.831
Chandler 1.322
Houston 1.254
Woodbridge 1.232
Moscow 1.133
Santa Clara 1.101
Jacksonville 1.090
Wilmington 991
Seattle 960
Beijing 859
Hong Kong 824
Cambridge 777
Hefei 717
Ann Arbor 647
Seoul 618
Siena 529
Princeton 514
Nanjing 392
Los Angeles 315
Munich 264
Milan 251
Boardman 249
The Dalles 237
Helsinki 236
New York 218
Florence 196
San Mateo 175
São Paulo 172
Ho Chi Minh City 167
Buffalo 159
San Diego 131
Dearborn 126
Rome 125
Dong Ket 122
Nanchang 112
Hanoi 107
Bengaluru 106
Shanghai 98
London 94
Redondo Beach 87
Hebei 79
Shenyang 79
Tianjin 76
Columbus 74
Tokyo 68
Turku 67
Nuremberg 65
Lappeenranta 62
Warsaw 62
Kunming 58
Chicago 57
Rio de Janeiro 57
Brussels 56
Council Bluffs 55
Düsseldorf 52
Izmir 52
Menlo Park 52
Denver 51
Stockholm 51
Jiaxing 50
Jinan 50
Changsha 47
Atlanta 46
San Francisco 45
Montreal 44
Guangzhou 41
Toronto 41
Norwalk 40
Johannesburg 39
Brooklyn 38
Phoenix 38
Belo Horizonte 37
Frankfurt am Main 37
Poplar 36
Portsmouth 36
San Jose 36
Turin 36
Tashkent 35
Falls Church 34
Hangzhou 34
Washington 34
Zhengzhou 34
Lauterbourg 33
Brno 32
Chennai 31
Dhaka 31
Orem 31
Porto Alegre 31
Curitiba 30
Abidjan 29
Baghdad 28
Bologna 27
Brasília 26
Amsterdam 25
Da Nang 25
Totale 36.687
Salva come PNG Salva come JPEG
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 804
null 398
Mycosis Fungoides: a therapeutical review 368
MACOP-B versus F-MACHOP regimen in the treatment of high grade Non-Hodgkin’s Lymphomas 341
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 304
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 296
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 286
Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome 285
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 280
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 273
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 271
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 271
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 271
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 268
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 265
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 262
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 258
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 258
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 253
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 252
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 252
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia 251
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 250
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 249
Second generation proteasome inhibitors in multiple myeloma 243
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 242
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 241
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 236
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 235
Central nervous system multiple myeloma 234
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 234
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 233
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 229
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 229
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 228
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 228
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 227
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 225
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 223
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 222
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 221
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 221
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 220
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 219
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 219
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 218
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 215
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 213
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 210
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 210
New perspectives for patients with primary CNS lymphoma 209
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 209
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 206
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses 204
Emerging drugs in chronic myelogenous leukaemia 204
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 204
Peptide vaccines for hematological malignancies: a missed promise? 203
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 203
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 203
A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid? 201
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 200
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 200
Primary Nasopharyngeal Hodgkin Lymphoma 198
FLT3 inhibitors in the management of acute myeloid leukemia 197
Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis 196
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 196
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 195
A solitary uterine relapse in T-cell Acute Lymphoblastic Leukaemia: CT features and pathologic correlation 194
Daratumumab efficacy in extramedullary orbital myeloma 194
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial 193
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 193
Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data 193
A novel t(6;7)(p24;q21) in a chronic myelocytic leuckemia in complete cytogenetic remission after therapy with imatinib mesylate 192
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 191
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 191
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 190
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 190
Treatment of smoldering multiple myeloma 188
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 188
Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases 187
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 187
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 186
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 186
Evolving treatments in multiple myeloma patients with renal failure 185
Hyperlipidemia in a myeloma patient after bortezomib treatment 185
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 185
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 184
Extramedullary myeloma relapses 184
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML working party analysis 184
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 183
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 183
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 183
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 181
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 181
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature 180
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 180
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice 180
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 179
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 178
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry 177
Totale 22.704
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.177
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.177
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.341 0 0 0 0 0 563 297 771 472 408 390 440
2021/20223.602 262 436 248 322 150 148 136 139 198 395 413 755
2022/20235.126 326 339 617 698 500 1.011 128 468 521 68 331 119
2023/20244.507 173 116 358 327 165 1.008 1.369 393 59 118 80 341
2024/20259.521 326 498 913 534 1.044 534 288 613 805 476 980 2.510
2025/202614.522 1.767 3.186 2.420 2.584 3.981 584 0 0 0 0 0 0
Totale 55.199